Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | 4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma

Jeffrey Weber • 4 Sep 2020
ESMO 2020
Melanoma Antibodies Ipilimumab Nivolumab
CheckMate 238

Jeffrey Weber, MD, PhD, of Perlmutter Cancer Center, New York, NY, updates us on the 4-year follow-up results of the randomized, Phase III CheckMate 238 study (NCT02388906), comparing adjuvant nivolumab versus ipilumumab in preventing recurrence of disease after complete resection in patients with stage III/IV melanoma. This study showed that nivolumab continued to demonstrate improved recurrence-free survival (RFS) and distant metastases-free survival (DMFS) vs ipilumumab at 4-years in patients with stage III/IV melanoma at high risk of reccurence. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Jeffrey Weber

Individualized antigen therapy in melanoma
1:30
Individualized antigen therapy in melanoma
Jeffrey Weber • 2 Jun 2024
3-year update from the KEYNOTE-942 trial: mRNA-4157 (V940) + pembrolizumab in resected melanoma
1:05
3-year update from the KEYNOTE-942 trial: mRNA-4157 (V940) + pembrolizumab in resected melanoma
Jeffrey Weber • 2 Jun 2024
Tocilizumab with ipilimumab and nivolumab in unresectable melanoma
1:00
Tocilizumab with ipilimumab and nivolumab in unresectable melanoma
Jeffrey Weber • 2 Jun 2024
INTerpath-001: V940, a neoantigen therapy, with pembrolizumab in melanoma
0:46
INTerpath-001: V940, a neoantigen therapy, with pembrolizumab in melanoma
Jeffrey Weber • 2 Jun 2024

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals